Cardinal Health reached its highest share level in 52 weeks following a series of bullish research notes from major brokerages. Wells Fargo raised its price objective from 221 to 237 and maintained an overweight rating, while UBS lifted its target from 185 to 220 with a buy recommendation. Citigroup upgraded the stock from neutral to buy and increased its target to 244, and TD Cowen boosted its forecast from 183 to 225. Across fourteen buy ratings and two holds, the consensus target now stands at 216.33, reflecting broad analyst confidence in the stock’s near-term trajectory.

In its most recent quarter, Cardinal Health generated revenue of 64.01 billion dollars, up 22.4% year-over-year, and reported earnings per share of 2.55, beating consensus by 0.33. Despite a modest net margin of 0.68% and a negative return on equity of 84.37%, management issued guidance for full-year EPS in the range of 9.65 to 9.85, compared with the consensus estimate of 7.95. The strong top-line growth was driven by both branded and generic pharmaceutical distribution as well as expanded logistics services.

Cardinal Health declared a quarterly dividend of 0.5107 per share, equating to an annualized payout of 2.04 and representing a 1.0% yield. With a payout ratio of 30.77%, the company continues to balance reinvestment in growth initiatives with returning capital to shareholders. The most recent ex-dividend date was January 2, reflecting the firm’s commitment to a stable and sustainable distribution policy.

The company’s market capitalization stands at 50.67 billion dollars, trading on a forward P/E of 32.16 and a PEG ratio of 1.52, while its beta of 0.65 underscores lower volatility relative to the broader market. Institutional investors hold 87.17% of shares outstanding, highlighting significant professional backing. The 50-day and 200-day moving averages are 205.19 and 174.32 respectively, indicating positive momentum in the context of a multi-month uptrend.